GW679769 has not yet been approved in the US, EU or Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


GW679769 studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
GW679769/903 II A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of GW679769 (30 mg and 90 mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects with Primary Insomnia
MAD106599 I A randomized, double-blind, placebo-controlled, crossover study to explore the effects of morning administration of GW679769 (30 mg and 90 mg), alprazolam (1.0 mg) and diphenhydramine (50 mg) on daytime cognition and psychomotor function in healthy subjects